New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry's business model.
For Patrick Lindsay, providing decision support across the full product life cycle is no stretch goal—it's today's fact of life
Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible—hope.
Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.
Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."
Fading growth; overstretched governments; and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, lifealtering diseases.
Editorial Director William Looney discusses the five essential characteristics exhibited by the more than 200 men and women selected by Pharmaceutical Executive as Emerging Pharma Leaders
The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China—ironically, the country touted as guarantor of our industry's future.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial